Drug Trial Radar · NCT06583031
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
385
Actual
Start
Oct 9, 2024
Primary completion
Oct 9, 2025
Study completion Oct 9, 2025
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.
Conditions
- RSV Infection
- hMPV
Interventions
RSV/hMPV vaccine dose A1Biological
Suspension for injection. Route of administration: IM injection
RSV/hMPV vaccine dose A2Biological
Suspension for injection. Route of administration: IM injection
RSV/hMPV vaccine dose A3Biological
Suspension for injection. Route of administration: IM injection
RSV/hMPV vaccine dose B1Biological
Suspension for injection. Route of administration: IM injection
RSV/hMPV vaccine dose B2Biological
Suspension for injection. Route of administration: IM injection
RSV/hMPV vaccine dose B3Biological
Suspension for injection. Route of administration: IM injection
RSV/hMPV vaccine dose C1Biological
Suspension for injection. Route of administration: IM injection
RSV/hMPV vaccine dose C2Biological
Suspension for injection. Route of administration: IM injection
RSV/hMPV vaccine dose C3Biological
Suspension for injection. Route of administration: IM injection
RSV/hMPV vaccine dose 1Biological
Suspension for injection. Route of administration: IM injection
RSV/hMPV vaccine dose 2Biological
Suspension for injection. Route of administration: IM injection
RSV/hMPV vaccine dose 3Biological
Suspension for injection. Route of administration: IM injection
Monovalent RSV VaccineBiological
Suspension for injection. Route of administration: IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of any unsolicited systemic Adverse Events (AEs) reported within 30 minutes after vaccinationTime frame: On Day 1
- Presence of solicited injection site and systemic reactions (ie, pre-listed in the participant's diary and in the eCRF (electronic case report form) occurring through 7 days after vaccinationTime frame: Day 1 through day 8
- Presence of unsolicited AEs reported through 28 days after vaccinationTime frame: Day 1 through day 29
- Presence of SAEs (Serious Adverse Events) and AESIs (Adverse Events of Special Interest) throughout the study (ie, through 6 months after vaccinationTime frame: SAE: Screening through day 181; AESI: Day 1 through day 181
- Presence of out-of-range biological test results (including shift from baseline values) through 7 days after vaccinationTime frame: Screening through day 8
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Site # 0361004
Botany, New South Wales, Australia
Site # 031001
Brookvale, New South Wales, Australia
Site # 0361006
Miranda, New South Wales, Australia
Site # 0361002
Wollongong, New South Wales, Australia
Site # 0361003
Herston, Queensland, Australia
Site # 0361005
South Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.